title: Introduction of our new associate editor.
abstract: Annick Desjardins, MD, FRCPC, speaks to Roshaine Gunawardana, Managing Commissioning Editor: Annick Desjardins is Associate Professor within the Department of Neurology and is the Director of Clinical Research at The Preston Robert Tisch Brain Tumor Center at Duke. In 2003, Dr Desjardins completed her residency in Adult Neurology at the Universite de Sherbrooke, Quebec, Canada. Following a 2-year fellowship in neuro-oncology at The Preston Robert Tisch Brain Tumor Center at Duke, she joined the Center as faculty, in July 2005. She is a Fellow of the Royal College of Physicians of Canada. She has been the Principal Investigator on over 30 therapeutic trials in neuro-oncology, including investigator initiated and international multicenter studies, and has held several Investigational New Drug applications. She has over 80 peer-review publications and six book chapters. She has written invited expert reviews for Hospital Pharmacy Europe, Nature Reviews Neurology, Clinical Care Options and MEDscape CME. She is reviewer for Neuro-Oncology, Cancer, Journal of Neuro-Oncology, Clinical Cancer Research, Expert Review of Anticancer Therapy, Cancer Research, Molecular Cancer Therapeutics and Future Oncology.
authors.forename: Annick
authors.initials: A
authors.lastname: Desjardins
authors.forename: Roshaine
authors.initials: R
authors.lastname: Gunawardana
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D002170:Canada; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D010820:Physicians; D017955:Poliovirus / Q000235:genetics; D011643:Publishing; D014481:United States
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab